MRC-AML11 protocol flow chart.
DAT 3 + 10: daunorubicin 50 mg/m2 slow intravenous (IV) push on days 1, 3, and 5; cytarabine 100 mg/m2 12-hourly IV push on days 1 to 10; thioguanine 100 mg/m2 12-hourly orally on days 1 to 10. ADE 10 + 3 + 5: daunorubicin 50 mg/m2 slow IV push on days 1, 3, and 5; cytarabine 100 mg/m2 12-hourly IV push on days 1 to 10; etoposide (VP-16) 100 mg/m2 IV (1-hour infusion) on days 1 to 5. MAC: mitozantrone 12 mg/m2 IV (30-minute infusion) on days 1 to 3; cytarabine 100 mg/m2 12-hourly IV push on days 1 to 5. DAT 2 + 5: as DAT 3 + 10 but daunorubicin on days 1 and 3 only and cytarabine and thioguanine on days 1 to 5 only. ADE 5 + 2 + 5: as ADE 10 + 3 + 5 but daunorubicin on days 1 and 3 only and cytarabine on days 1 to 5 only. MAC 2 + 5: as MAC 3 + 5 but mitozantrone on days 1 and 3 only. DAT 2 + 7: as DAT 3 + 10 but daunorubicin on days 1 and 3 only and cytarabine and thioguanine on days 1 to 7 only. COAP: cyclophosphamide 600 mg/m2 IV on day 1; vincristine 1.5 mg/m2 (maximum 2 mg/m2) on day 1; cytarabine 100 mg/m2 subcutaneous injection on days 1 to 5; prednisolone 60 mg/m2 orally on days 1 to 5.
